Delving into the Latest Updates on Angimmune LLC with Synapse

Overview

Basic Info

Introduction

Angimmune LLC, a clinical stage biotech venture, was established by Dr. David Neville alongside his colleagues, Dr. Yuan-Yi Liu and Dr. Jung-Hee Woo, leveraging their pioneering immunotoxin technology developed at NIH. With exclusive NIH licensing, Angimmune operates from the American Red Cross Holland Laboratory in Rockville, Maryland, advancing innovative research in immunotherapy.

Tags

Neoplasms

Immune System Diseases

Hemic and Lymphatic Diseases

Protein drugs

Antibody toxin conjugate

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Protein drugs	1
Antibody toxin conjugate	1

Top 5 Target	Count

CD3(T cell surface glycoprotein CD3)	1

This study evaluates the effectiveness - as judged by complete response - of a single four-day treatment with the fusion protein A-dmDT390-bisFv(UCHT1) compared to oral Zolinza (Vorinostat), in a randomized 2-arm trial after a maximum of 12 months of treatment. Patient eligibility is stage IB/IIB mycosis fungoides with mSWAT < 50 who have never had lymphoid disease or a prior bone marrow / HSCT transplant.

Start Date01 Jan 2017

Sponsor / Collaborator

Angimmune LLC

[+16]

NCT02990416 / Unknown statusPhase 1/2

Phase I/II Trial of the A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

This study evaluates the effectiveness of adding a single four-day treatment of the fusion protein A-dmDT390-bisFv(UCHT1) - plus single palliative tumor radiation - with standard of care KEYTRUDA (Pembrolizumab) therapy for the treatment of metastatic melanoma. The results will be measured by comparing the combined therapy to historical data of KEYTRUDA alone.

Start Date01 Jan 2017

Sponsor / Collaborator

Angimmune LLC

NCT01888081 / TerminatedPhase 1/2

Phase I/II Trial of A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for the Treatment of Stage IV Melanoma

The purpose of this trial is to study A-dmDT390-bisFv(UCHT1) in combination with ionizing irradiation for the treatment of stage IV melanoma, a disease that is essentially incurable with median overall survival periods that range from 8-16 months.

Start Date01 Feb 2014

Sponsor / Collaborator

Angimmune LLC

[+1]

100 Clinical Results associated with Angimmune LLC

Login to view more data

0 Patents (Medical) associated with Angimmune LLC

Login to view more data

7

Literatures (Medical) associated with Angimmune LLC

01 Sep 2024·Transplantation

P.547: Tolerogenic properties of CD3 immunotoxin induction therapy and progress toward clinical trials in transplantation.

Author: Kaplan, Bruce ; Duran-Struuck, Raimon ; Liu, Andrew ; Hu, Huaizhong ; Huang, Christene A. ; Neville, Paul ; Pomfret, Elizabeth ; Wang, Zhirui ; Chen, Su ; Mathes, David W. ; Navarro-Alvarez, Nalu ; Wang, Zhaohui

28 Oct 2023·Scientific reports

Recombinant immunotoxin induces tumor intrinsic STING signaling against head and neck squamous cell carcinoma.

Article

Author: Teng, Shaolei ; Xie, Guiqin ; Yang, Cuicui ; Shan, Liang ; Pang, Xiaowu ; Gu, Xinbin ; Wu, Tzyy-Choou ; Liu, Yuanyi

The innate immune stimulator of interferon genes (STING) pathway is known to activate type I interferons (IFN-I) and participate in generating antitumor immunity. We previously produced hDT806, a recombinant diphtheria immunotoxin, and demonstrated its efficacy against head and neck squamous cell carcinoma (HNSCC). However, it's unknown whether the tumor-intrinsic STING plays a role in the anti-HNSCC effects of hDT806. In this study, we investigated the innate immune modulation of hDT806 on HNSCC. hDT806 significantly upregulated the level of STING and the ratio of p-TBK1/TBK1 in the HNSCC cells. Moreover, intratumoral hDT806 treatment increased the expression of STING-IFN-I signaling proteins including IFNA1, IFNB, CXCL10 and MX1, a marker of IFN-I receptor activity, in the HNSCC xenografts. Overexpression of STING mimicked the hDT806-induced upregulation of the STING-IFN-I signaling and induced apoptosis in the HNSCC cells. In the mouse xenograft models of HNSCC with STING overexpression, we observed a significant suppression of tumor growth and reduced tumor weight with increased apoptosis compared to their control xenograft counterparts without STING overexpression. Collectively, our data revealed that hDT806 may act as a stimulator of tumor-intrinsic STING-IFN-I signaling to inhibit tumor growth in HNSCC.

01 Jan 2017·BioMed Research InternationalQ3 · BIOLOGY

Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges

Q3 · BIOLOGY

ReviewOA

Author: Gu, Xinbin ; Zhu, Shaowei ; Wang, Paul C. ; Shan, Liang ; Liu, Yuanyi

Recombinant immunotoxins (RITs) refer to a group of recombinant protein-based therapeutics, which consists of two components: an antibody variable fragment or a specific ligand that allows RITs to bind specifically to target cells and an engineered toxin fragment that kills the target cells upon internalization. To date, over 1,000 RITs have been generated and significant success has been achieved in the therapy of hematological malignancies. However, the immunogenicity and off-target toxicities of RITs remain as significant barriers for their application to solid tumor therapy. A group of RITs have also been generated for the treatment of glioblastoma multiforme, and some have demonstrated evidence of tumor response and an acceptable profile of toxicity and safety in early clinical trials. Different from other solid tumors, how to efficiently deliver the RITs to intracranial tumors is more critical and needs to be solved urgently. In this article, we first review the design and expression of RITs, then summarize the key findings in the preclinical and clinical development of RIT therapy of glioblastoma multiforme, and lastly discuss the specific issues that still remain to forward RIT therapy to clinical practice.

100 Deals associated with Angimmune LLC

Login to view more data

100 Translational Medicine associated with Angimmune LLC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Phase 2 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

A-dmDT390-bisFv(National Institutes of Health) ( CD3 )	Acute Lymphoblastic Leukemia More	Phase 2
hDT806	Squamous Cell Carcinoma of Head and Neck More	Preclinical